Bicycle therapeutics to present pharmacokinetic and safety evaluation of lead btc® molecules in phase 1/2 trials at the 2024 asco annual meeting

Cambridge, england & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that emerging phase 1/2 clinical pharmacokinetic (pk) and safety data for bicycle toxin conjugates® (btc® molecules) bt8009 and bt5528 demonstrating differentiated safety and tolerability profiles will be presented at the 2024 american society for.
BCYC Ratings Summary
BCYC Quant Ranking